BIODESIX INC
Biomarker-based diagnostics provider.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Biodesix's stock, with a target price of $3.1, indicating strong growth potential.
Financial Health
Biodesix is generating solid revenue and cash flow, with strong profit margins indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BDSX
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial adoption watch
Investors may watch test uptake and reimbursement; these drive revenue growth, though adoption can be slower than expected and affect results.
Technology and data
Proteomics plus machine learning underpin the offering and could differentiate products, but robust clinical validation is essential.
Partners and scale
Partnerships with hospitals and pharma can extend reach and credibility, yet competitive pressures and payment systems can limit impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
UnitedHealth Group Incorporated
Provides healthcare services to individuals and organizations
CVS Health Corporation
CVS Health is a healthcare company that provides pharmacy, health insurance, and other healthcare services.
HCA Holdings, Inc.
A healthcare services company dedicated to providing high quality, cost effective care.
